Dr Agarwal's Eye Hospital Ltd (DAEHL)

About:

  • Chain of 149 eye hospitals (as on June 30, 2023) across domestic and international destinations.
  • Operates a hub and spoke delivery model: well-equipped tertiary hospitals supported by secondary care, primary care hospitals and outreach clinics.
  • Key markets for the company include Tamil Nadu, Karnataka, Maharashtra, Gujarat, Punjab, Telangana, Andhra Pradesh, Kerala, and West Bengal.
  • Offers services in the eye-care segment including Cataract, Glaucoma, Laser Correction, Cornea and Refractive, Retina etc.
  • Parent → Dr Agarwals Health Care Ltd. (DAHCL) | Owns 71.75% of the shareholding. This used to be below 60% till FY12. It was increased to 70+% in FY13 using open offer. | Provides centres on lease to DAEHL | Planned to expand its current network of 150+ centres to over 300+ centres in the next 3 years | Intends to establish more than 100 primary eye clinics in tier 2 and tier 3 towns in the next couple of years. Africa is another important geography for it where it has a network presence of 15 hospitals. It will also deepen the presence in Kenya, Zambia, and Tanzania and looks to add 10 centres across these countries. Source of funding:
    • May 10, 2022: Dr. Agarwal’s Health Care Ltd. raises over 1,000 Crore funding from TPG Growth and Temasek.The company also raised â‚ą270 crores investment from Temasek in 2019.
    • August 17, 2023: Dr Agarwals Health Care Ltd. raises 650 crores from TPG and Temasek.
  • Added more than 33 centres in the last one year ended fiscal 2023 and 10 centers in for Q1FY24
  • 2019: With an aspiration to bring standardisation in procedures, to ensure regular trainings and Continuing Medical Education (CME) of our doctors, the Clinical Board was setup. We began this journey in 2018 to equip our doctors with necessary skills and provide our patients world class service consistently across branches. two key initiatives undertaken in the Current financial year. Clinical audits were performed at all branches and learnings were shared with the branch teams. We are in the process of continuously monitoring the audit findings. The electronic medical records system implemented in the last year has enabled remote and frequent auditing. Secondly, the Branch Safety Scorecard (BSSC) was introduced. BSSC evaluates every branch on 5 parameters Endophthalmitis, Reporting of incidents, Aqueous meets Vitreous (AQMV), Critical events and Customer Happiness.
  • 2023: Entered the Kerala market with a state-of-the-art branch in Cochin.
  • Cathedral Road centre to be launched in FY24 with state-of-the-art infrastructure, and world class eye care facilities being provided to the needy under a single roof.
  • 80+% of FY23 revenue came from surgeries.
  • OPM % jumped from 18% in FY19 to 27% in FY20 due to decrease in rent expenses [Other Expenses].
  • Parent Vs Listed Entity Numbers (Source: Latest Credit Report and Screener.in):
DAHCL (Parent) DAEHL (Listed Entity)
Figures in Rs. Crores 2022 2021 2022 2021
Operating income 698 472 201 140
Reported profit after tax 43 -59 37 24

Opportunities:

  • Promoter team with right blend of Clinical and managerial expertise.
  • Aging population (above 60 years) with growing affluence.

Threats:

  • Elective nature of procedure.
  • Leasehold premises. In the event of non-renewal, businesses may face disruptions.
  • Geographically concentrated operations with modest growth in scale amidst stiff competition.

Risks:

  • Limited disclosures in public filings. For instance, I could not find rationale for Africa operations.
  • Ramp up and stabilization of operations for new centers incur higher costs during the initial phases.
  • Plan to raise debt~200Cr. in the listed business for the upcoming growth.

KPIs:


Overall:

Expansion plan of the parent indicates a 25~30% cagr in Income and Operating Income for the next 3 yrs. Even the expected additional borrowing of 200 Cr. seems serviceable, considering the operating cash flow of the last 5 yrs. Although existing D/E of ~2+ looks high, the debt mainly consists of lease liabilities that have maturity after 5 or more Yrs. and do not strain the immediate cash flow.

Disc: No Position.Shared the above for collabrative learning.
Sources: Public Filings - ARs, Company Website, Credit ratings

11 Likes

Thanks for sharing. Looks promising story from HC sector. Currently, it has run-up a lot and would wait to see how well they execute. Overall, post covid HC / Hospitals have seen one way interest from investors. Would be interesting to see if capex in this sector is actually eps accretive.

Thank you sharing the initial summary @Surender . I am also tracking this for quite some time now as it repeatably comes in a lot of screeners. Unfortunately the company is not doing any investor calls or presentations. So very difficult to get any clear picture of any future prospects. For me right now the main concern is the deb/eq (1.7 as of 20 jan 2024). So hoping for their first investor call/presentation in future to get some idea.

1 Like

194cr of lease liabilities is shown under borrowings. Actual debt is 34 cr long term and 6cr short term debt. So D/E is near 0.3.

1 Like

Thanks for the clarification @Hemanth_Kumar. That’s a good positive to know. Although I am not invested, but it does look like an interesting idea to pursue if we can get some visibility of their roadmap.

1 Like

Dr Agarwal Eye Hospital Limited

Founded by Dr Jaiveer Agarwal in 1957 under Agarwal group of eye hospitals, fun fact – he was the first in India to introduce Refractive keratoplasty (Basically a surgery which many of us or our family member might have undergone through to cure our eye deficiency in order to view without the need of glasses, he was the owner of Padma Bhusana Award for the same in 2006, he was the President of the All India Ophthalmological Society in 1992.

Currently Prof. Amar Agarwal Son of Dr. Jaiveer Agarwal undertakes the operations of the group companies, his education qualifications: He completed M.B.B.S. degree in February 1983 from Madras Medical College, Madras University. His further qualifications include M.S.(Ophtha) in July 1986 from Ahmedabad Civil Hospital, University of Gujarat, FRCS in October 1986 from the Royal College of Surgeons of Edinburgh, United Kingdom and F.R.C.Ophth in October 1988 from Royal College of Ophthalmologists, London, United Kingdom.

He is the first to remove cataracts through a 0.7 mm tip with the technique called Microphakonit. He has also discovered No anesthesia cataract surgery and FAVIT a new technique to remove dropped nuclei.

He is also the first surgeon to implant a new mirror telescopic IOL (LMI) for patients with age related macular degeneration. He has also been the first in the world to implant a Glued IOL

In this a PC IOL is fixed in an eye without any capsules using fibrin glue. The Malyugin ring for small pupil cataract surgery was also modified by him as the Agarwal modification of the Malyugin ring for miotic pupil cataract surgeries with posterior capsular defects. Dr. Agarwal’s eye hospital has also done for the first time an Anterior segment transplantation in a 4-month-old child with anterior staphyloma

Hospital sector’s tailwind

In 2023 private market and public market saw a huge amount and quantum of deals for

Hospital sector 🡪 30,000 crores to be precise in private market itself

Majority of them being led by Blackstone, TPG and Temasek Holdings,

Infact as per above article Temasek is likely to invest 10 more billion in India where in 2023 it spent 20% of it (2 Billion) in acquisition of 59% of Manipal hospital

Source: https://x.com/bastionresearch/status/1778057029694914974

Some of the interesting deals:

  1. Manipal Enterprise Health: In April 2023, Temasek Holdings (Private) Limited a Singapore’s based sovereign wealth fund acquired a 41% stake in Ranjan Pai led Manipal Enterprise Health for Rs. 16,000 Cr. This took the total stake held by the sovereign wealth fund from 18% to 59% and valued the company at Rs. 40,000 Cr making it the largest healthcare deal to date.
  2. CARE Hospital: In October 2023, private equity giant Blackstone acquired a majority stake in CARE Hospitals which in turn had inked a definitive agreement to buy KIMS health. The deal was worth ~$1 Bn ($700Mn for CARE and $360-420Mn).
  3. General Atlantic had acquired Ujala Cygnus, a leading hospital chain in northern India. Though the financial details are not disclosed, the deal has valued the chain at Rs. 1,600 Cr.
  4. Parent entity of Dr. Agarwal Eye Hospital limited 🡪 Dr Agarwal Healthcare limited 🡪 Raised money from TPG and Tamsek 🡪 Now they are aiming for the IPO of around 3000 crores of Share Sale 🡪 where the entity will be valued itself at 16-18k crores, the consol revenue of the group entity is around 1000 crores (Out of which listed subsidiary’s revenue is around 300 crores) assuming that since listed entity operates under asset light model and giving 20-30% discount on upper price band the proportionate value allocation of subsidiary should be around 3.5K crores against the value current of 1.5K crores + Capex coming in live can make the bet more attractive

Idea Generation:

Traveling to work last few days have been seeing poster of Dr Agarwal Hospital on every 2nd bus of Best, I thought i must be imagining it but turn out i wasn’t, I noticed this pattern during 4 days of office in a week and every day Near Rickshaw Stand i witnessed multiple best bus passing with Hospital’s advertisement, While traveling in Rickshaw i noticed that, that Rickshaw also had the same poster and I asked for the review, apparently the hospital is going all in on Marketing, according to the driver, they are going big in Mumbai and wanted to get hold of the public,

Quite incidentally my spotify subscription had expired and being too lazy to renew it, I kept using it as it was and Dr Agarwal’s Advertisement popped up in spotify too,

I checked their 2023 marketing expenses immediately (2024 aren’t out yet) and not surprisingly they are up 3.5x.!!!

Checks out that they were big in South but now they are going big in Mumbai and hence heavy marketing.

I checked google review for Mumbai hospitals and see the reviews → 15K reviews and average rating is 4.9…!

If they go big in Mumbai and Gujarat and They go successful this will be my biggest winner in Hospitals after Artemis and Kovai


Thesis:

As the economy’s per capital income grows beyond 2,500-3000$ the incremental expenses towards health increases that’s common observation among the economies which have transformed from developing to developed economy.

Most of the hospitals have had dream run up some of my favorite in this field where Artemis and Kovai, Kovai has had the best practice in terms of business operations and Artemis has followed them a long way!

Specifically Kovai has had dream run in last 10 years, anyways moving towards the Main topic, unlike other hospitals eye care hospitals are way different, why?

Because eye surgery are generally for very short span of time, may be for 1-2 hours and 99% of surgery don’t require patients to stay in the hospital after the surgery and if they do the ALOS may be even 1-2 day meaning the requirement of the extended facilities is very minute for them. The space requirement is also far less and hence capital requirement of such business model is very less comparing the same to Full fledged hospital.

The group structure of this entity is such that Agarwal Health care limited the holding company is also involved in the same business activity but the good part is as follows, unlike other hospitals which put up their capital, buys the hospital, operates it and breaks even at PBP level 7-8 years time period here they lease up the land/building from the Holding company and it’s associates consideration of which is rent this allows them to make money before their competitor, Now I know that the Brand is the core competitive advantage for the hospitals but they are trying something new in terms of maintaining the cashflow for the company and scaling it fast,

The holding company is backed by 2 of the biggest funds, TPG and Tamsek, together they own 60% of the holding company, it’s highly unlikely that they’ll sell/Fuck up the subsidiary which gives them 30%-35% of the revenue,

The company is backed by some of the best and visionary founders, they have contributed to the society more than any promoter in Hospital field that i know of. This makes me believe in the high corporate governance standard, there’s nothing concerning that i found in last 17 year’s annual report too.

the books checks out corporate governance checks out,

Asset base is expanding quickly they could have more than 500 crores of assets in less than a year generating enough revenue even at 1x asset turnover,

they’ll generating revenue equivalent to 500 crores and 150 crores EBITDA, although this isn’t normal hospital but one can still assume that they can be sold at 20-25x EBITDA, which is equivalent to the proportionate value that we arrived allocating the value of holding company to the subsidiary,

Only anti thesis:

Holding company is in the same business, why will the corporate structure be kept messy if the holding company and it’s subsidiary is in the same business sharing the same name?

Chances of both company merging and since subsidiary trading at discount to the allocated value the swap potentially harming to the listed company’s shareholder might be the concern,

As taking the benefit of the inefficiency is something most of this PE funds do, hence something to look out for
image

Summary

It’s a company backed by some of the mind who added huge value for the people of bharat. Whether it be the Founder or his Son both of them contributed greatly in the medical field, not only that Amar Agarwal bought in Investors tuning in his business mindset, helping the holding company grow to the size of $2 billion.

Now they are growing the company fairly with a huge speed expanding asset base to 500 crores the value buy kicks in.

There’s immense value in the company backed by professional management.

It possesses the highest level of capital efficiency, It generates ROE north of 30% from Day 1 where other hospitals require 8-10 years to reach that level. It’s fairly new operation model if it’s successful it’ll be generating the flush of cash, much larger than any hospital in it’s early stage and will be able to roll on cashflow for new investment and since Major part of new investment will just be upfront lease deposits + equipments, the scale will be much much faster, net of leases they generated around 60 crores of Free cash flow in 2024 alone, considering the same it’s not hard for them to earn 100 crores of FCFE in next 3-4 years, even faster in 2 years if Capex goes as per plan, they are going aggressive as mentioned in the Idea generation section. I wouldn’t have it any other way, If Holding company’s IPO is supposed to come it’s fairly certain they’ll bring it when the company’s is in best possible case, for that they’ll require Subsidiary to be in the best earnings and that part is still pending,

I personally see this entity worth half a billion at least in next 2 years

Annual Report – 2009

Compensation – Dr. Amar Agarwal – MD at that point – 2,50,000 p.m. 🡪 PAT + Depreciation was merely 5.5 crores than why such high remuneration (taking into account 30 LPA is just for one board member)? Total remuneration paid to family members = 1.2 crores out of 5.5 crores of cash earned
image

Turnover in 2009 🡪 73 crores to 2024 🡪300 crores, what took so long for the company
2009 🡪 Performance analysis


Auditor’s concerns:

Note: 8


FS – Analysis

There has been no dilution in equity in last 17 years, apart from mandatory MSP criteria of SEBI implemented in 2011 due to which dilution took place in 2014!!!



Looking at the Fx Assets schedule – Weird thing is there’s no building which is one of the core asset of the hospitals as they are quite asset heavy and require 7-8 years of PBP – SOIC – this can be one of the core thesis of investment refer in Thesis section

Rough reason is their parent company is a big hospital chain they lease out their buildings from them: deposit is a part of the same only

image
More than 3.69 crores were paid in rents 🡪 the same goes to promoters through parent entity More than 3.69 crores were paid in rents 🡪 the same goes to promoters through parent entity

Annual Report – 2010

Resolutions required to increase the remuneration of Dr. Amar and Athiya from 2,50,000 to 3,00,000 a month each? And Anosh Agarwal 2,50,000 a month

The reason might be both Founder and his wife who used to draw their salary of 30 LPA died during the year, total family remuneration will be 78,75,000 which is less than 1.2 crores withdrawn 🡪 Green flag, cause if they wanted they would have compensated for the same through tits bits here or there

Performance analysis for FY:

Total network of hospitals 🡪 30

FS – Analysis


All though very very minuscule amount not even 25 lakhs but why is vehicle loan outstanding for a eye chain hospital, I mean this has to be for promoters right cause generally eye chain don’t have ambulance
Trend I observed 🡪 Income from optical increasing as a % of revenue, generally that’s a higher margins business



Why so unconfident lol…!
image
there are significant increase in RPT
Annual Report – 2011

Expansion announcement through borrowings:
image

Increase in word of mouth it seems


Current year’s remuneration of family – Works around 1.2 crores, Lol, seems too early to declare as a green flag but anyways in last 3 years they have scaled a lot due to operating leverage seems fair enough that they haven’t increase remuneration at family level i.e., 1.2 ka 1.2 only
image

FS – Analysis

Again a vehicle loan :woman_shrugging::man_shrugging:

Impairment loss charged to surgical appliances

Annual Report – 2013

Look at ROCE and ROE no’s whenever the hospital’s in it’s beginning phase it’s very unlikely it’ll earn ROCE more than 10-15% even the giant like Medanta, NH, HCG aren’t able to do so, but their business model and way it operates makes it lucrative for them to earn consistently above average ROCE and ROE (Refer below exhibits for Comparable ROCE and ROE to understand the differentiating factor in business model)
HCG

image

NH
image

Medanta
image

In compression of above all there’s Dr Agarwal earning 35% ROE (Comparing ROCE with ROE as major hospital chain stated above own and operates their own building hence there’s no need of lease adjustment but here major capital structure item consists of Lease liability, hence considering the same ROE is taken as KPI)
Network of hospital 🡪 50

In 2012 the company’s promoters increased their stake through open offer

Annual Report – 2014
image

image
Post asking for increment in leasing cap limit – the Ramp up was good almost 20% CAGR in next 2 years (From 2015)


Why??

image
There has been no increase in promoter remuneration in past 6 years?
Apart from lease of course but that are at FMV.

Auditor’s concern

Annual Report – 2015
image


New CAPEX based on leases Special resolution


PAT + Depreciation from 2008 to 2015 almost doubled but the remuneration of family hovers around the same range.

Annual Report – 2016


From 300,000 to 700,000? May be due to the fact that Adil and Anosh Agarwal (Family members) retired from the company, but still 1.6 crores seems excessive on cashflow of 11-12 crores

Note: Major hospitals 🡪 Vellore and Jaipur (Very big in south India as they are from TN and Rajasthan which isn’t surprising since Agarwal means they are more likely to be Marwadi hence Rajasthan seems to be a good place for familiarity )

Operating in 22 location in India

The Charge against the company’s loan 🡪 Equitable mortgage on property held by director/owner



Jump in auditor’s remuneration by almost 3x 🡪 Quite understandable actually as Auditor is Big 4

Expansion

Annual Report – 2017

As explained in thesis part building hospital is part of core brand building 🡪 you’ll require a significant time to even build a reputable hospital, for example if I’m going to Fortis as a regular person for my annual check up, it’s very unlikely that I’ll change it to Kovai or Say Artemis.! We can observe the significant improvement in margins post 2017-18 from 16 to 20% and they are currently at 30%.! Maturities of investment highlighted here should be considered here

Question: If My Sanjay Anand is Shareholder how is he Independent? same goes for CS of the company

Auditor’s concern:

My personal view: it’s of demonization times: for a company doing revenue of 150 crores INR 759,000 of old notes compliance lapse isn’t big deal practically

Annual Report – 2023

Why would you say something like this in the first place, your work is to do business and make bottom line and not to worry about what investors are doing to the stock price.

image

Part of major expansion plan?

image

Books clean as they can be

Total Rent expenses v/s RPT rent expenses

Roughly the cash outflow = Rent expenses in total 🡪 so roughly out of 8 crores, 7 crores is RP rent which is a good thing as mentioned in above section of thesis

image
Some of Board’s remuneration: Special look at previous employment history

Industry overview:
image
image

Disclaimer → Not Invested still contemplating about my purchase, I can buy it at any time and sell to, Do consider your risk and rewards while investing into the company based on my data complied.

10 Likes

Anyone here has tried comparing “Clove Dental” with Dr Agarwal. I was trying to do some comparison.

  • Clove Dental was valued at 191Mn$ in Dec 2022 (that’s the recent I could find) and Dr Agarwal was valued at around 220-230Mn$ as of now.
  • Clove dental revenue was 241 Cr in FY 2023, Dr Agarwal did 268Cr in FY 23 and 319 in FY24.
  • This makes the valuation of Dr Agarwal at around MCap to Revenue multiplier to around 6 (1869/319) as of now and clove dental on Dec 22 at 6.75 (1628/241). 1628 is 194mn$. So on this parameter, Dr Agarwal is cheaper.
  • India’s dental care market was valued at $653 million in 2022 and is expected to grow to $1,339 million by 2030. The eye care industry, which includes services such as cataract, glaucoma, retina and squint, is valued at around USD 1.4 billion in India. So looks like the market of eyecare is bigger than dental care.

I am not sure of profit of Clove Dental could not find that anywhere.

While both are of similar size right now and the market potential of eye care is bigger than dental care so room to grow for Dr Agarwal is more. This along with t he fact that only 10% of the eye care market is organized looks like there is a huge opportunity here.

Disc: Not invested but planning to buy soon.

3 Likes